NRX Pharmaceuticals (NRXP) Cash & Equivalents Growth (3y) (2020 - 2026)
NRX Pharmaceuticals (NRXP) Cash & Equivalents Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -15.41% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 8.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 47.78% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -23.18% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 14.34% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.45% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -14.22% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.85% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -27.97% |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 21.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.96% |
| Dec 31, 2025 | -27.01% |
| Sep 30, 2025 | -26.71% |
| Jun 30, 2025 | -50.93% |
| Mar 31, 2025 | -48.47% |
| Dec 31, 2024 | -62.61% |
| Sep 30, 2024 | -65.48% |
| Jun 30, 2024 | -47.84% |
| Mar 31, 2024 | -53.68% |
| Dec 31, 2023 | 35.22% |
| Sep 30, 2023 | 90.50% |
| Jun 30, 2023 | 146.78% |
| Mar 31, 2023 | 489.01% |
| Dec 31, 2022 | 183.79% |
| Sep 30, 2022 | 354.57% |
| Jun 30, 2022 | 2,501.66% |
| Mar 31, 2022 | 2,706.80% |
| Dec 31, 2021 | 1,255.70% |
| Sep 30, 2021 | 696.03% |
| Jun 30, 2021 | 357.70% |